Kash Biotech Express

Antibodies discovery, IHC

kashbiotech
Amyloid Beta Elisa anti-Human beads Biotin blocking peptide Cell Based Elisa coli recombinant colorimetric Cy3 Cy7 gel gene Glutamate Assay Kit high Lipase Assay Kit Monomethyl Auristatin E Sa B Gal Sa Beta Gal Senescence Assay Senescence Beta Galactosidase Staining Kit Spoligotyping Transformation Assay Trap Assay Kit

Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic

Despite substantial progress in confronting the global HIV-1 epidemic since its inception in the 1980s, better approaches for both treatment and prevention will be necessary to end the epidemic and remain a top public health priority. Antiretroviral therapy (ART) has been effective in extending lives, but at a cost of lifelong adherence to treatment. Broadly neutralizing antibodies (bNAbs) are directed to conserved regions of the HIV-1 envelope glycoprotein trimer (Env) and can block infection if present at the time of viral exposure. The therapeutic application of bNAbs holds great promise, and progress is being made toward their development for widespread clinical use. Compared to the current standard of care of small molecule-based ART, bNAbs offer: (1) reduced toxicity; (2) the advantages of extended half-lives that would bypass daily dosing requirements; and (3) the potential to incorporate a wider immune response through Fc signaling. Recent advances in discovery technology can enable system-wide mining of the immunoglobulin repertoire and will continue to accelerate isolation of next generation potent bNAbs. Passive transfer studies in pre-clinical models and clinical trials have demonstrated the utility of bNAbs in blocking or limiting transmission and achieving viral suppression.

These studies have helped to define the window of opportunity for optimal intervention to achieve viral clearance, either using bNAbs alone or in combination with ART. None of these advances with bNAbs would be possible without technological advancements and expanding the cohorts of donor participation. Together these elements fueled the remarkable growth in bNAb development. Here, we review the development of bNAbs as therapies for HIV-1, exploring advances in discovery, insights from animal models and early clinical trials, and innovations to optimize their clinical potential through efforts to extend half-life, maximize the contribution of Fc effector functions, preclude escape through multiepitope targeting, and the potential for sustained delivery.

 

Symptoms, antibody levels and vaccination attitude after asymptomatic to moderate COVID-19 infection in 200 healthcare workers

 

Aim: In Germany, the willingness to be vaccinated against COVID-19 is rather low among medical staff. We collected data on symptoms, antibody titers and vaccination readiness from clinic employees at a municipal clinic who had already been through a COVID-19 infection (asymptomatic to moderate). We also examined the antibody titers for their possible importance as an individual decision-making aid with regard to vaccination.

 

Method: 200 employees of our municipal clinics were included in the study. COVID-19 antibody determination was performed using an ELISA (EUROIMMUN™, PerkinElmer, Inc. Company). The participants were given an anonymous questionnaire containing anthropometrical issues, symptoms of the infection and questions concerning the vaccination decision. Finally, the antibody levels were reported to the participants and the attitude towards a vaccination was reevaluated.

 

Results: In all 200 participants who had already gone through a COVID-19 infection, 75 employees were in favor of a vaccination (37.5%), 96 were opposed to vaccination (48%), and 29 were undecided (14.5%). In the different occupational groups, the positive trend in terms of willingness to be vaccinated was highest among physicians and is least among nurses. The antibody results showed considerable variation in titer levels and therefore did not correlate with disease severity in asymptomatic to moderately ill persons. We also observed a pro-vaccination trend with increasing age of the participants. The specifically-asked symptom of cutaneous hyperesthesia during COVID-19 infection occurred in 5% of the participants.

 

Conclusion: In medical personnel who had already suffered from a COVID-19 infection, the willingness to receive a vaccination tends to be highest among physicians, and lowest in nurses, and increases with age. For the vast majority of those affected, knowledge of the antibody titers only reinforces the vaccination decision made beforehand and thus does not contribute to a change in vaccination decision. The specifically-requested symptom of cutaneous hyperesthesia during COVID-19 infection was unexpectedly frequent.

kashbiotech
kashbiotech

Engineering a novel IgG-like bispecific antibody against enterovirus A71

Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection. The development of monoclonal antibodies (mAbs) has demonstrated promise as a novel therapy for the prevention and treatment of infectious diseases. Several medical conditions have been treated using bispecific or multi-specific antibodies that recognize two or more distinct epitopes simultaneously. However, bispecific or multi-specific antibodies often encounter protein expression and product stability problems.

In this study, we developed an IgG-like bispecific antibody (E18-F1) comprising two anti-EVA71 antibodies: E18 mAb and llama-derived F1 single-domain antibody. E18-F1 was demonstrated to exhibit superior binding affinity and antiviral activity compared with E18 or F1. Additionally, E18-F1 not only improved survival rate, but also reduced clinical signs in human SCARB2 receptor (hSCARB2) transgenic mice challenged with a lethal dose of EVA71. Altogether, our results reveal that E18-F1 is a simple format bispecific antibody with promising antiviral activity for EVA71.

Myelin Oligodendrocyte Glycoprotein-antibody-associated Disorder Presenting with Corticomeningeal Encephalitis prior to the Onset of Optic Neuritis

We herein report a case of myelin oligodendrocyte glycoprotein-antibody-associated disorder (MOG-AD) presenting with corticomeningeal encephalitis. The patient exhibited oral ulceration, a mild impairment of consciousness, fever, nausea, nuchal rigidity, positivity for human leukocyte antigen type B51, and neutrophil-dominant pleocytosis and interleukin-6 level in cerebrospinal fluid (CSF). Magnetic resonance imaging (MRI) revealed a right temporal lesion with leptomeningeal gadolinium enhancement.

The initial diagnosis was neuro-Behçet’s disease presenting with meningoencephalitis; however, a cell-based assay detected anti-MOG antibody in the serum and CSF and the patient also experienced bilateral optic neuritis. After administering steroid therapy, his neurologic symptoms and CSF abnormalities improved along with the disappearance of gadolinium enhancement and the lesion on MRI. This case suggests that MOG-AD may present with corticomeningeal encephalitis prior to the onset of optic neuritis.

Anti-VEGF antibody
PAab09391 100 ug
EUR 463.2

anti- VEGF antibody
FNab09391 100µg
EUR 658.5
Description: Antibody raised against VEGF

Anti- VEGF antibody
FNab09933 100µg
EUR 658.5
Description: Antibody raised against VEGF

Anti-VEGF antibody
STJ97787 200 µl
EUR 236.4
Description: Rabbit polyclonal to VEGF.

Anti-VEGF antibody
STJ119887 100 µl
EUR 471.6
Description: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.

Polyclonal Goat anti-GST α-form
GST-ANTI-1 50 uL
EUR 336

Polyclonal Goat anti-GST μ-form
GST-ANTI-2 50 uL
EUR 336

Polyclonal Goat anti-GST p-form
GST-ANTI-3 50 uL
EUR 336

Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin
1-CSB-EP606027NAH
  • EUR 733.20
  • EUR 370.80
  • EUR 2192.40
  • EUR 1126.80
  • EUR 1461.60
  • EUR 476.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin expressed in E.coli

Anti-VEGF Antibody Clone VEGF/1063, Unconjugated-100ug
7422-MSM1-P1 100ug
EUR 513.6

Anti-VEGF-C Antibody
A00623 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for VEGF-C Antibody (VEGFC) detection.tested for IHC, WB in Human, Mouse, Rat.

Anti-VEGF/Vegfa Antibody
A00045 100ug/vial
EUR 352.8

Anti-VEGF/VEGF164 Antibody
A00045-1 100ug/vial
EUR 352.8

Anti-VEGF/Vegfa Antibody
A00045-2 100ug/vial
EUR 352.8

Anti-VEGF/VEGFA Antibody
PA1080 100ug/vial
EUR 400.8

Anti-VEGF/VEGFA Antibody
PB9071 100ug/vial
EUR 400.8

Anti-VEGF-C antibody
STJ96662 200 µl
EUR 236.4
Description: Rabbit polyclonal to VEGF-C.

Anti-VEGF-B antibody
STJ96851 200 µl
EUR 236.4
Description: Rabbit polyclonal to VEGF-B.

anti-VEGF Receptor 3
YF-PA23727 50 ul
EUR 400.8
Description: Mouse polyclonal to VEGF Receptor 3

anti-VEGF Receptor 1
YF-PA11817 50 ug
EUR 435.6
Description: Mouse polyclonal to VEGF Receptor 1

anti-VEGF Receptor 1
YF-PA11818 100 ug
EUR 483.6
Description: Rabbit polyclonal to VEGF Receptor 1

Anti-VEGF Neutralizing Antibody
79478-1 50 µg
EUR 355
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species.

Anti-VEGF Neutralizing Antibody
79478-2 100 g
EUR 460
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species.

VEGF receptor Flt-1 (F56), Peptide Aptamer, FITC labelled
AP-334-F 1 mg Ask for price

anti-Cyclophilin F
YF-PA25484 50 ul
EUR 400.8
Description: Mouse polyclonal to Cyclophilin F

anti-Apolipoprotein F
YF-PA10244 50 ul
EUR 435.6
Description: Mouse polyclonal to Apolipoprotein F

anti-Apolipoprotein F
YF-PA10245 50 ug
EUR 435.6
Description: Mouse polyclonal to Apolipoprotein F

anti-Apolipoprotein F
YF-PA10246 100 ug
EUR 483.6
Description: Rabbit polyclonal to Apolipoprotein F

anti-Cathepsin F
YF-PA15821 50 ul
EUR 435.6
Description: Mouse polyclonal to Cathepsin F

anti-Cathepsin F
YF-PA15822 50 ug
EUR 435.6
Description: Mouse polyclonal to Cathepsin F

VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, FITC labelled
AP-336-F 1 mg Ask for price

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-b-48T 48T
EUR 591.6
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids.

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-b-96T 96T
EUR 769.2
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids.

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Hu-48T 48T
EUR 403.2
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Hu-96T 96T
EUR 510
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Mu-48T 48T
EUR 522
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Mu-96T 96T
EUR 673.2
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Ra-48T 48T
EUR 544.8
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Ra-96T 96T
EUR 704.4
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-b-48Tests 48 Tests
EUR 619.2

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-b-96Tests 96 Tests
EUR 859.2

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Hu-48Tests 48 Tests
EUR 396

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Hu-96Tests 96 Tests
EUR 540

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Mu-48Tests 48 Tests
EUR 536.4

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Mu-96Tests 96 Tests
EUR 741.6

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Ra-48Tests 48 Tests
EUR 564

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Ra-96Tests 96 Tests
EUR 781.2

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-b-48Tests 48 Tests
EUR 592.8

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-b-96Tests 96 Tests
EUR 820.8

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Hu-48Tests 48 Tests
EUR 380.4

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Hu-96Tests 96 Tests
EUR 517.2

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Mu-48Tests 48 Tests
EUR 514.8

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Mu-96Tests 96 Tests
EUR 709.2

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Ra-48Tests 48 Tests
EUR 540

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Ra-96Tests 96 Tests
EUR 746.4

VEGF
MO15067 500 ug
EUR 1092

VEGF
LF-PR009 10 ug
EUR 306
Description: VEGF protein

VEGF
PR15028 10 ug
EUR 553.2

Anti-VEGF-A Humanized Antibody
A2136-100 100 µg
EUR 612

Anti-VEGF Rabbit Monoclonal Antibody
M00045-1 100ug/vial
EUR 476.4
Description: Rabbit Monoclonal VEGF Antibody. Validated in Flow Cytometry, IP, IF, IHC, ICC and tested in Human, Mouse.

Anti-VEGF Receptor 2 (2A2)
YF-MA13909 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (4A2)
YF-MA13910 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (2C5)
YF-MA13911 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (4B5)
YF-MA13912 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (4F1)
YF-MA13913 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 3 (5B6)
YF-MA10355 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (5F11)
YF-MA13094 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (6F9)
YF-MA13095 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (5B5)
YF-MA13096 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (4D1)
YF-MA13097 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (2E3)
YF-MA13098 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (1C1)
YF-MA13099 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (6B7)
YF-MA13100 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF (Bevacizumab), humanized Antibody
A1045-100 each
EUR 601.2

VEGF receptor KDR and Flt-1 (v107), Peptide Aptamer, FITC labelled
AP-335-F 1 mg Ask for price

VEGF-stimulated Human Umbilical Vein Endothelial Cell, Peptide Aptamer, FITC labelled
AP-338-F 1 mg Ask for price

VEGF-stimulated human umbilical vein endothelial cells, Peptide Aptamer, FITC labelled
AP-339-F 1 mg Ask for price

Mouse IgG F(c)-FITC conjugate (isotype control)
20008-Fc-F 100 ug
EUR 196.8

Rabbit IgG F(c)-FITC conjugate, isotype control
20009-Fc-F 100 ug
EUR 196.8

Goat IgG F(ab')2 fragment-FITC conjugate
20011-FAB2-F 100 tests
EUR 242.4

Mouse IgG F(ab')2-FITC conjugate (isotype control)
20008-Fab2-F 100 ug
EUR 196.8

Rabbit IgG F(ab')2-FITC conjugate, isotype control
20009-FAb2-F 100 ug
EUR 196.8

VEGF-A(VEGF/1063) Antibody
BNC041063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC041063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCAP1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCAP1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCB1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCB1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCP1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCR1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC941063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC941063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCA1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC811063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC811063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNUB1063-100 100uL
EUR 250.8
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody
BNUB1063-500 500uL
EUR 549.6
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody
BNCH1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCH1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC881063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC881063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC611063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC611063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC681063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC681063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC471063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC471063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC401063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC401063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC431063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC431063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC551063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC551063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC801063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC801063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC051063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC051063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC701063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC701063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNUM1063-50 50uL
EUR 474
Description: Primary antibody against VEGF-A(VEGF/1063), 1mg/mL

VEGF/ Rat VEGF ELISA Kit
ELA-E0143r 96 Tests
EUR 1063.2

Anti-HLA-F Purified
11-823-C100 0.1 mg
EUR 234

Anti-Cyclin F Antibody
A06781 100ul
EUR 476.4
Description: Rabbit Polyclonal Cyclin F Antibody. Validated in IHC, WB and tested in Human.

Anti-HLA-F PE
1P-823-C100 0.1 mg
EUR 397.2

Anti-Cathepsin F antibody
PAab01307 100 ug
EUR 426

Anti-Cystatin F antibody
PAab02182 100 ug
EUR 463.2

Anti-HLA-F antibody
PAab03911 100 ug
EUR 494.4

Anti-HLA-F antibody
PAab03912 100 ug
EUR 494.4

anti- Cathepsin F antibody
FNab01307 100µg
EUR 606.3
Description: Antibody raised against Cathepsin F

anti- Cystatin F antibody
FNab02182 100µg
EUR 658.5
Description: Antibody raised against Cystatin F

anti- HLA-F antibody
FNab03911 100µg
EUR 702
Description: Antibody raised against HLA-F

anti- HLA-F antibody
FNab03912 100µg
EUR 702
Description: Antibody raised against HLA-F

Anti-HLA-F antibody
STJ112420 100 µl
EUR 332.4
Description: This gene belongs to the HLA class I heavy chain paralogues. It encodes a non-classical heavy chain that forms a heterodimer with a beta-2 microglobulin light chain, with the heavy chain anchored in the membrane. Unlike most other HLA heavy chains, this molecule is localized in the endoplasmic reticulum and Golgi apparatus, with a small amount present at the cell surface in some cell types. It contains a divergent peptide-binding groove, and is thought to bind a restricted subset of peptides for immune presentation. This gene exhibits few polymorphisms. Multiple transcript variants encoding different isoforms have been found for this gene. These variants lack a coding exon found in transcripts from other HLA paralogues due to an altered splice acceptor site, resulting in a shorter cytoplasmic domain.

Anti-APOBEC3D/F antibody
STJ91636 200 µl
EUR 236.4
Description: Rabbit polyclonal to APOBEC3D/F.

Anti-Arylsulfatase F antibody
STJ91715 200 µl
EUR 236.4
Description: Rabbit polyclonal to Arylsulfatase F.

Anti-Cyclin F antibody
STJ92545 200 µl
EUR 236.4
Description: Rabbit polyclonal to Cyclin F.

Anti-Cyclophilin F antibody
STJ92550 200 µl
EUR 236.4
Description: Rabbit polyclonal to Cyclophilin F.

Anti-F beta antibody
STJ93162 200 µl
EUR 236.4
Description: Rabbit polyclonal to FTbeta.

Anti-hnRNP F antibody
STJ93564 200 µl
EUR 236.4
Description: Rabbit polyclonal to hnRNP F.

Anti-PIG-F antibody
STJ95089 200 µl
EUR 236.4
Description: Rabbit polyclonal to PIG-F.

Anti-Cathepsin F antibody
STJ70694 100 µg
EUR 430.8

Anti-HLA-F antibody
STJ24030 100 µl
EUR 332.4
Description: This gene belongs to the HLA class I heavy chain paralogues. It encodes a non-classical heavy chain that forms a heterodimer with a beta-2 microglobulin light chain, with the heavy chain anchored in the membrane. Unlike most other HLA heavy chains, this molecule is localized in the endoplasmic reticulum and Golgi apparatus, with a small amount present at the cell surface in some cell types. It contains a divergent peptide-binding groove, and is thought to bind a restricted subset of peptides for immune presentation. This gene exhibits few polymorphisms. Multiple transcript variants encoding different isoforms have been found for this gene. These variants lack a coding exon found in transcripts from other HLA paralogues due to an altered splice acceptor site, resulting in a shorter cytoplasmic domain.

Anti-Apolipoprotein F antibody
STJ71651 100 µg
EUR 430.8

Anti-Apolipoprotein F (1D5)
YF-MA10047 100 ug
EUR 435.6
Description: Mouse monoclonal to Apolipoprotein F

Custom Testing of Samples for Antibodies Snake Venom (anti-venins from Horse/Sheep) by ELISA
570-100-CUX Custom Ask for price

Anti-VEGF Receptor 3/FLT4 Antibody
A01276-2 100ug/vial
EUR 400.8

Anti-VEGF Receptor 3/FLT4 Antibody
A01276-3 100ug/vial
EUR 400.8

Anti-VEGF Receptor 1/FLT1 Antibody
A00534 100ug/vial
EUR 352.8

Anti-VEGF Receptor 1/FLT1 Antibody
A00534-1 100ug/vial
EUR 352.8

Anti-VEGF Receptor 2/KDR Antibody
A00901-2 100ug/vial
EUR 400.8

Anti-VEGF Receptor 2/Kdr Antibody
A00901-3 100ug/vial
EUR 400.8

Anti-VEGF Receptor 1/FLT1 Antibody
PA1399 100ug/vial
EUR 352.8

Anti-VEGF Receptor 1/FLT1 Antibody
PA1966 100ug/vial
EUR 352.8

Anti-VEGF Receptor 1/FLT1 Antibody
PA1966-1 100ug/vial
EUR 352.8

Anti-VEGF Receptor 1/FLT1 Antibody
PA1966-2 100ug/vial
EUR 352.8

Anti-VEGF Receptor 2/KDR Antibody
PA1989 100ug/vial
EUR 400.8

Anti-VEGF Receptor 2/KDR Antibody
PB9429 100ug/vial
EUR 352.8

VEGF antibody
70R-11863 100 ul
EUR 536.4
Description: Goat polyclonal VEGF antibody

VEGF antibody
70R-11864 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody
70R-12327 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody
70R-12328 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody
70R-12329 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody
70-VR20 50 ug
EUR 392.4
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody
10-2585 250 ug
EUR 590.4
Description: Mouse monoclonal VEGF antibody

VEGF antibody
10-2586 100 ug
EUR 289.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody
70R-13764 100 ug
EUR 418.8
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF Antibody
48707-100ul 100ul
EUR 399.6

VEGF Antibody
48707-50ul 50ul
EUR 286.8

VEGF protein
30R-AV008 2 ug
EUR 152.4
Description: Purified recombinant Murine VEGF protein

VEGF antibody
10R-7735 500 ug
EUR 678
Description: Mouse monoclonal VEGF antibody

VEGF antibody
10R-V101ax 100 ug
EUR 571.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody
10R-V101b 200 ug
EUR 805.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody
10R-V109A 500 ug
EUR 327.6
Description: Mouse monoclonal VEGF antibody

VEGF Antibody
ABF5131 100 ug
EUR 525.6

VEGF antibody
70R-VG001 100 ug
EUR 392.4
Description: Affinity purified Goat polyclonal VEGF antibody

VEGF antibody
70R-VR001x 50 ug
EUR 392.4
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody
70R-VR003 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody
70R-VR004 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody
70R-VR006 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody
PAab09933 100 ug
EUR 463.2

VEGF, CF
PR15028CF 10 ug
EUR 553.2

VEGF 121
PR15029 5 ug
EUR 498

VEGF 162
PR15030 25 ug
EUR 553.2
Tags:
Alternative non-antibody scaffolds for molecular recognition.
kashbiotech